Neurophet Launches Joint Study with VHIR on ‘Neurophet AQUA MS’, Accelerating AI Algorithm Validation
Publish Date: 2026-05-26 09:00:00
Source Domain: www.prnewswire.com
- Collaboration Announcement: Neurophet, an AI solution company, announced a joint research partnership with Vall d’Hebron Institut de Recerca (VHIR) to develop AI diagnostics for multiple sclerosis.
- Focus on AI Algorithms: The collaboration aims to leverage large-scale clinical brain MRI datasets to develop AI algorithms that can detect key lesion biomarkers in multiple sclerosis.
- Development of AQUA MS Software: Neurophet aims to use VHIR’s datasets to integrate and enhance its AQUA MS software, which is designed for analyzing brain images of multiple sclerosis patients.
- Key Biomarker Detection: The project will focus on creating detection algorithms for the Central Vein Sign (CVS) and Paramagnetic Rim Lesions (PRL), which are important imaging biomarkers for multiple sclerosis.
- Market Focus: The enhanced AI technology from Neurophet aims to establish a strategic foothold in the U.S. and European markets, where the prevalence of multiple sclerosis is higher.
- Leveraging VHIR’s Expertise: VHIR will contribute de-identified MRI datasets and expertise, with Dr. Alex Rovira Cañellas leading this effort in enhancing the clinical reliability of Neurophet’s AI technology.
- Product Background: Neurophet’s AQUA MS received FDA 510(k) clearance in October 2024 and is part of a suite of AI-driven products for brain disorder diagnosis and treatment solutions.
- Strategic Focus: Neurophet, founded in 2016, is dedicated to developing AI solutions for brain disorders, emphasizing the importance of clinical data in enhancing the efficacy of its technologies.
